Norihiko Terada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Norihiko Terada has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Hiromichi Suzuki
Department of Infectious Diseases, University of Tsukuba Hospital, Tsukuba, Japan
7 shared publications - Shigeyuki Notake
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 3058558, Japan
7 shared publications - Yusaku Akashi
Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba
7 shared publications - Atsuo Ueda
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan
6 shared publications - Koji Nakamura
Department of Clinical Laboratory, Tsukuba Medical Center Hospital, 1-3-1 Amakubo, Tsukuba, Ibaraki, 305-8558, Japan
6 shared publications - Yuto Takeuchi
Department of Infectious Diseases, University of Tsukuba Hospital, 2-1-1 Amakubo, Tsukuba, Ibaraki, 305-8576, Japan; Division of Infectious Diseases, Department of Medicine, Tsukuba Medical Center Hospital, 1-3-1 Amakubo Tsukuba, Ibaraki, 305-8558, Japan
6 shared publications
Latest Publications
- Open Access
- 20 April 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (6) , 102974
Prospective multicenter evaluation of the QuickNavi-Campylobacter assay in stool specimens
- 20 April 2026
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 32 (6) , 102974
Open AccessProspective multicenter evaluation of the QuickNavi-Campylobacter assay in stool specimens
- 19 November 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102563
Identification of causative and non-causative microorganisms of nephrostomy tube-associated pyelonephritis among patients with malignancy
- 19 November 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (2) , 102563
Identification of causative and non-causative microorganisms of nephrostomy tube-associated pyelonephritis among patients with malignancy
- Open Access
- 15 November 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (22) , 3117-3118
Syphilitic Hepatitis
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 15 November 2024
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 63 (22) , 3117-3118
Open AccessSyphilitic Hepatitis
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 19 June 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102449
Extended-spectrum β-lactamase-producing Plesiomonas shigelloides isolated from the stool of a Japanese traveler returning from Rwanda: A case report
- 19 June 2024
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (1) , 102449
Extended-spectrum β-lactamase-producing Plesiomonas shigelloides isolated from the stool of a Japanese traveler returning from Rwanda: A case report
- Open Access
- 7 February 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (2) , e0298018
To treat or not to treat: Assessing the role of anti-enterococcal therapy for intra-abdominal infections in patients with cancer
The clinical significance of enterococci in intra-abdominal infections, particularly those caused by multiple organisms, remains unclear. There are no definitive guidelines regarding the use of empiric therapy with antimicrobial agents targeting enterococci. In this study, we evaluated the impact of the initial antimicrobial therapy administration of anti-enterococcal agents on the treatment of intra-abdominal infections in patients with cancer in whom enterococci were isolated from ascitic fluid cultures. This retrospective study was conducted at Shizuoka Cancer Center between January 1, 2014, and December 31, 2020, on all adult patients with cancer with enterococci in their ascitic fluid cultures. The primary outcome was all-cause mortality, and the secondary outcomes were composite outcomes consisting of three components (mortality, recurrence, and treatment failure) and the risk factors associated with all-cause mortality and composite outcomes. In total, 103 patients were included: 61 received treatment covering enterococci, and 42 did not. The mortality rates did not differ significantly between the treated and untreated groups (treated: 8/61 [13.1%]; untreated: 5/42 [11.9%]; p = 1.00). Additionally, no significant difference was observed between the groups in terms of composite outcomes (treated group: 11/61 [18.0%]; untreated group: 9/42 [21.4%]; p = 0.80). Multivariate analysis showed that performance status (PS2–4; p < 0.0001) was an independent risk factor for mortality. The composite outcome was also significantly higher for PS2–4 (p = 0.007). Anti-enterococcal treatment was not associated with mortality or the composite outcome. In patients with cancer and intra-abdominal infections caused by enterococci, anti-enterococcal therapy was not associated with prognosis, whereas PS2 or higher was associated with prognosis. The results of this study suggest that the initial routine administration of anti-enterococcal agents for intra-abdominal infections may not be essential for all patients with cancer. To substantiate these findings, validation by a prospective randomized trial is warranted.
- 7 February 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (2) , e0298018
Open AccessTo treat or not to treat: Assessing the role of anti-enterococcal therapy for intra-abdominal infections in patients with cancer
The clinical significance of enterococci in intra-abdominal infections, particularly those caused by multiple organisms, remains unclear. There are no definitive guidelines regarding the use of empiric therapy with antimicrobial agents targeting enterococci. In this study, we evaluated the impact of the initial antimicrobial therapy administration of anti-enterococcal agents on the treatment of intra-abdominal infections in patients with cancer in whom enterococci were isolated from ascitic fluid cultures. This retrospective study was conducted at Shizuoka Cancer Center between January 1, 2014, and December 31, 2020, on all adult patients with cancer with enterococci in their ascitic fluid cultures. The primary outcome was all-cause mortality, and the secondary outcomes were composite outcomes consisting of three components (mortality, recurrence, and treatment failure) and the risk factors associated with all-cause mortality and composite outcomes. In total, 103 patients were included: 61 received treatment covering enterococci, and 42 did not. The mortality rates did not differ significantly between the treated and untreated groups (treated: 8/61 [13.1%]; untreated: 5/42 [11.9%]; p = 1.00). Additionally, no significant difference was observed between the groups in terms of composite outcomes (treated group: 11/61 [18.0%]; untreated group: 9/42 [21.4%]; p = 0.80). Multivariate analysis showed that performance status (PS2–4; p < 0.0001) was an independent risk factor for mortality. The composite outcome was also significantly higher for PS2–4 (p = 0.007). Anti-enterococcal treatment was not associated with mortality or the composite outcome. In patients with cancer and intra-abdominal infections caused by enterococci, anti-enterococcal therapy was not associated with prognosis, whereas PS2 or higher was associated with prognosis. The results of this study suggest that the initial routine administration of anti-enterococcal agents for intra-abdominal infections may not be essential for all patients with cancer. To substantiate these findings, validation by a prospective randomized trial is warranted.
- Open Access
- 28 December 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (7) , 590-596
Distribution of ticks and their possession of spotted fever group Rickettsia in Ibaraki prefecture
- 28 December 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (7) , 590-596
Open AccessDistribution of ticks and their possession of spotted fever group Rickettsia in Ibaraki prefecture
- Open Access
- 7 March 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (7) , 654-659
Prospective study of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 among mainly symptomatic patients in Japan
- 7 March 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (7) , 654-659
Open AccessProspective study of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 among mainly symptomatic patients in Japan
- Open Access
- 1 January 2023
- Published by Wiley in European Journal of Cancer Care
- Vol. 2023 (1)
Impact of Early Chemotherapy Resumption on the Outcome after Staphylococcus aureus Bacteremia in Patients with Solid Tumors: A Retrospective Study in a Single Tertiary Cancer Center in Japan
Objective . Staphylococcus aureus bacteremia (SAB) in patients with solid tumors poses a dilemma between infection control and cancer treatment. We aimed to explore whether early resumption of chemotherapy yielded unfavorable outcomes in oncologic patients with SAB. Methods . We retrospectively reviewed patients who received chemotherapy within 90 days of SAB onset from 2011 to 2020. We divided patients who resumed chemotherapy into two groups by the median time from the negative blood culture to the chemotherapy resumption. We investigated the association with treatment failure, which included recurrence after completion of SAB treatment, relapse during antibiotics therapy, 90‐day all‐cause mortality after initiation of antibiotics, and 30‐day all‐cause mortality after the resumption of chemotherapy. Results . Among the 78 eligible patients, 36 patients resumed chemotherapy. The median interval to the chemotherapy resumption was 17.5 days. Two patients in the early resumption group and one in the late resumption group died within 90 days after initiating antibiotics. One patient in the early resumption group experienced SAB recurrence. None of the patients experienced SAB relapse or died within 30 days of resuming chemotherapy. Conclusion . Early resumption of chemotherapy may not be directly associated with unfavorable outcomes in oncological patients with SAB under appropriate infection management.
- 1 January 2023
- Published by Wiley in European Journal of Cancer Care
- Vol. 2023 (1)
Open AccessImpact of Early Chemotherapy Resumption on the Outcome after Staphylococcus aureus Bacteremia in Patients with Solid Tumors: A Retrospective Study in a Single Tertiary Cancer Center in Japan
Objective . Staphylococcus aureus bacteremia (SAB) in patients with solid tumors poses a dilemma between infection control and cancer treatment. We aimed to explore whether early resumption of chemotherapy yielded unfavorable outcomes in oncologic patients with SAB. Methods . We retrospectively reviewed patients who received chemotherapy within 90 days of SAB onset from 2011 to 2020. We divided patients who resumed chemotherapy into two groups by the median time from the negative blood culture to the chemotherapy resumption. We investigated the association with treatment failure, which included recurrence after completion of SAB treatment, relapse during antibiotics therapy, 90‐day all‐cause mortality after initiation of antibiotics, and 30‐day all‐cause mortality after the resumption of chemotherapy. Results . Among the 78 eligible patients, 36 patients resumed chemotherapy. The median interval to the chemotherapy resumption was 17.5 days. Two patients in the early resumption group and one in the late resumption group died within 90 days after initiating antibiotics. One patient in the early resumption group experienced SAB recurrence. None of the patients experienced SAB relapse or died within 30 days of resuming chemotherapy. Conclusion . Early resumption of chemotherapy may not be directly associated with unfavorable outcomes in oncological patients with SAB under appropriate infection management.
- Open Access
A prospective evaluation of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 in Japan
Introduction Rapid qualitative antigen testing has been widely used for the laboratory diagnosis of COVID-19 with nasopharyngeal samples. Saliva samples have been used as alternative samples, but the analytical performance of those samples for qualitative antigen testing has not been sufficiently evaluated. Methods A prospective observational study evaluated the analytical performance of three In Vitro Diagnostics (IVD) approved COVID-19 rapid antigen detection kits for saliva between June 2022 and July 2022 in Japan using real-time reverse transcription polymerase chain reaction (RT-PCR) as a reference. A nasopharyngeal sample and a saliva sample were simultaneously obtained, and RT-PCR was performed. Results In total, saliva samples and nasopharyngeal samples were collected from 471 participants (140 RT-PCR-positive saliva samples and 143 RT-PCR-positive nasopharyngeal samples) for the analysis. The median Ct values were 25.5 (interquartile range [IQR]: 21.9-28.8) for saliva samples and 17.1 (IQR: 15.5-18.7) for nasopharyngeal samples (p90% for saliva samples with a moderate-to-high viral load (CtConclusion COVID-19 rapid antigen detection kits with saliva showed high specificities, but the sensitivities varied among kits, and the analytical performance of saliva qualitative antigen detection kits was much worse than that of kits using nasopharyngeal samples.
Open AccessA prospective evaluation of three saliva qualitative antigen testing kits for the detection of SARS-CoV-2 in Japan
Introduction Rapid qualitative antigen testing has been widely used for the laboratory diagnosis of COVID-19 with nasopharyngeal samples. Saliva samples have been used as alternative samples, but the analytical performance of those samples for qualitative antigen testing has not been sufficiently evaluated. Methods A prospective observational study evaluated the analytical performance of three In Vitro Diagnostics (IVD) approved COVID-19 rapid antigen detection kits for saliva between June 2022 and July 2022 in Japan using real-time reverse transcription polymerase chain reaction (RT-PCR) as a reference. A nasopharyngeal sample and a saliva sample were simultaneously obtained, and RT-PCR was performed. Results In total, saliva samples and nasopharyngeal samples were collected from 471 participants (140 RT-PCR-positive saliva samples and 143 RT-PCR-positive nasopharyngeal samples) for the analysis. The median Ct values were 25.5 (interquartile range [IQR]: 21.9-28.8) for saliva samples and 17.1 (IQR: 15.5-18.7) for nasopharyngeal samples (p90% for saliva samples with a moderate-to-high viral load (CtConclusion COVID-19 rapid antigen detection kits with saliva showed high specificities, but the sensitivities varied among kits, and the analytical performance of saliva qualitative antigen detection kits was much worse than that of kits using nasopharyngeal samples.
- Open Access
- 20 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 257-262
Analytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant
- 20 November 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 29 (3) , 257-262
Open AccessAnalytical performance of the rapid qualitative antigen kit for the detection of SARS-CoV-2 during widespread circulation of the Omicron variant